About OxThera
OxThera is a company based in Stockholm (Sweden) founded in 2005. OxThera has raised $93.1 million across 6 funding rounds from investors including HHS, Idinvest Partners and Kurma Partners. OxThera offers products and services including Oxabact. OxThera operates in a competitive market with competitors including Evelo Biosciences, Calliditas Therapeutics, DermBiont, Vedanta Biosciences and Unicycive, among others.
- Headquarter Stockholm, Sweden
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Oxthera Ab
-
Annual Revenue
$252.23 K (USD)48as on Dec 31, 2019
-
Net Profit
-$19.97 M (USD)-38as on Dec 31, 2019
-
EBITDA
-
Total Equity Funding
$93.1 M (USD)
in 6 rounds
-
Latest Funding Round
$222.83 K (USD), Grant
Sep 01, 2019
-
Investors
HHS
& 11 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OxThera
OxThera offers a comprehensive portfolio of products and services, including Oxabact.
Orally administered treatment to reduce oxalate in Primary Hyperoxaluria patients.
People of OxThera
Unlock access to complete
Unlock access to complete
Funding Insights of OxThera
OxThera has successfully raised a total of $93.1M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $222.83 thousand completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Grant — $222,828
-
First Round
First Round
(11 Jul 2005)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2019 | Amount | Grant - OxThera | Valuation |
investors |
|
| Nov, 2016 | Amount | Series D - OxThera | Valuation | Life Sciences Partners , Ysios Capital | |
| Apr, 2014 | Amount | Series C - OxThera | Valuation | Kurma Partners |
Investors in OxThera
OxThera has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Idinvest Partners and Kurma Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments in life sciences businesses are managed.
|
Founded Year | Domain | Location | |
|
Ysios Capital is recognized as a leading life sciences investor.
|
Founded Year | Domain | Location | |
|
Investments are made by Sunstone in early-stage European companies.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OxThera
Financial Statements - OxThera
Oxthera Comparisons
Competitors of OxThera
OxThera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evelo Biosciences, Calliditas Therapeutics, DermBiont, Vedanta Biosciences and Unicycive, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed.
|
|
| domain | founded_year | HQ Location |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| domain | founded_year | HQ Location |
Microbial therapeutics for skin diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for infectious and autoimmune diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapies for kidney diseases are developed.
|
|
| domain | founded_year | HQ Location |
Provider of DNA-based pathogen testing kits
|
Frequently Asked Questions about OxThera
OxThera was founded in 2005.
OxThera is headquartered in Stockholm, Sweden.
OxThera is a funded company, having raised a total of $93.1M across 6 funding rounds to date. The company's 1st funding round was a Series C of $10.65M, raised on Jul 11, 2005.
Annual revenue of OxThera is $252.23K as on Dec 31, 2019.
Provider of microbial-based drug products to treat hyperoxaluria. They develop products, based on cell and enzyme-based proprietary technologies, for metabolic disorders based on excess oxalate from endogenous and exogenous sources. Oxabact delivers an orally delivered composition of live bacteria, Oxalobacter Formigenes, and is primarily targeting the orphan disease Primary Hyperoxaluria. The other product Oxazyme is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase for treatment of Hyperoxaluria and to prevent the formation of calcium-oxalate kidney stones, and in phase 3 of the clinical trial.
OxThera's top competitors include PathogenDX, Calliditas Therapeutics and Manus Bio.
OxThera offers Oxabact.
OxThera has 12 investors. Key investors include HHS, Idinvest Partners, Kurma Partners, Life Sciences Partners, and Q-Med.